Field of Science

  • in The Biology Files
  • in inkfish
  • in Life of a Lab Rat
  • in The Greenhouse
  • in PLEKTIX
  • in Chinleana
  • in RRResearch
  • in The Culture of Chemistry
  • in Disease Prone
  • in The Phytophactor
  • in The Astronomist
  • in Epiphenom
  • in Sex, Genes & Evolution
  • in Skeptic Wonder
  • in The Large Picture Blog
  • in Memoirs of a Defective Brain
  • in C6-H12-O6
  • in The View from a Microbiologist
  • in Labs
  • in Doc Madhattan
  • in The Allotrope
  • in The Curious Wavefunction
  • in A is for Aspirin
  • in Variety of Life
  • in Pleiotropy
  • in Catalogue of Organisms
  • in Rule of 6ix
  • in Genomics, Evolution, and Pseudoscience
  • in History of Geology
  • in Moss Plants and More
  • in Protein Evolution and Other Musings
  • in Games with Words
  • in Angry by Choice

Met/VEGFR/FGFR inhibitors by VS

ResearchBlogging.org

This one comes from a NCI group. Starting with a database of 3.5 million compounds, 175 prospective candidates were finally selected for inhibition of Met kinase by virtual screening based on filtering by size, log P, polarity, h-bond donors and acceptors etc. The 175 compounds were docked by GOLD and 70 were selected on the basis of force-field calculated protein-ligand interaction energies (always a risky endeavor, but for a similar series, errors may cancel). For paring down the compound set, an empirical pharmacophore based on the usual kinase interactions (eg. h-bonding to hinge residues and h-bonding to a crucial Tyr to keep the kinase locked in the inactive conformation) was used.

The 70 compounds bought from vendors were assayed in cell-free Met assays as well as HGF (hepatocyte growth factor) induced Met activation. 3 compounds were chosen with modest Met inhibition IC50 values of 0.6 and 40 µM. The IC50s for the intact cells were 30, 50 and 30 µM. In spite of this less than stellar inhibition performance, the three were tested for the inhibition of other kinases and found to inhibit VEGFR and FGFR to similar extents. Since the single-kinase inhibition paradigm seems to be called into question these days, one might as well diversify. The different inhibition values were rationalized on the basis of hydrogen bonding and other interactions (or the lack thereof) by docking. Wisely, docking and docking scores were not used for judging binding affinity, just the orientations of the compounds in the active sites.

The flavone-like looks of the compounds make me quite suspicious about PK and Tox. Only time will tell. But Met is emerging as a valuable target.

Reference:
Megan L. Peach, Nelly Tan, Sarah J. Choyke, Alessio Giubellino, Gagani Athauda, Terrence R. Burke, Jr., Marc C. Nicklaus and Donald P. Bottaro (2009)
Directed Discovery of Agents Targeting the Met Tyrosine Kinase Domain by Virtual Screening
J. Med. Chem ASAP

1 comment:

  1. I don't have an access to full text of this one but the abstract suggests to me yet another resounding failure of rational design.

    So, out of the library of 3.5 million compuonds, three low affinity and poor specificity ligands were found. Woa. So far as I can tell, humans' track record of playing god is not very good.

    ReplyDelete

Markup Key:
- <b>bold</b> = bold
- <i>italic</i> = italic
- <a href="http://www.fieldofscience.com/">FoS</a> = FoS